Article Text
PDF
Other content recommended for you
- Predicting and preventing the future: actively managing multiple sclerosis
- Neurofilament light chain as a biomarker in neurological disorders
- Update on disease-modifying therapies for multiple sclerosis
- Diagnosis and disease modifying treatments in multiple sclerosis
- Disease modification in multiple sclerosis: an update
- All you need to read in the other general journals
- Impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany between 2010 and 2018: real-world data from the German NeuroTransData multiple sclerosis registry
- Ocrelizumab appears to reduce relapse and disability in multiple sclerosis but quality of evidence is moderate
- ▼ Daclizumab for MS
- Disease modifying therapies for relapsing multiple sclerosis